Eiger BioPharmaceuticals, Inc.
EIGR
Classificação em ações
#36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preço da ação
$1.73
Última sincronização: 2025-06-17
Valor de mercado
$2.55M
Variação (1 dia)
-0.29%
Variação (1 ano)
-79.71%
País
US
Negociar Eiger BioPharmaceuticals, Inc. (EIGR)
Categoria
Healthcare
Receita da Eiger BioPharmaceuticals, Inc. (EIGR)
Receita em Dec 2023 TTM: $15.77M
De acordo com os últimos relatórios financeiros da Eiger BioPharmaceuticals, Inc., a receita atual da empresa (TTM) é $15.77M. Em 2022, a empresa obteve uma receita de $13.48M um aumento em relação a a receita do ano 2021, que foi de $12.14M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Eiger BioPharmaceuticals, Inc. de 2016 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $15.77M | 0.00% |
| 2023 | $15.77M | 16.98% |
| 2022 | $13.48M | 11.05% |
| 2021 | $12.14M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 79,937.41% |
US
|
|
| $2.23B | 14,025.40% |
US
|
|
| $15.74B | 99,718.22% |
AU
|
|
| $6.02B | 38,074.65% |
NL
|
|
| - | - |
CH
|
